← Back to Search

UPLIFT-AD for Alzheimer's Disease (UPLIFT-AD Trial)

N/A

Recruiting

Led By Kathleen T Unroe, MD, MHA

Research Sponsored by Indiana University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Long-stay resident in an enrolled nursing home defined as not paying through Medicare Part A at the enrolled facility

Has a diagnosis of moderate to severe ADRD, as measured on the Minimum Data Set (MDS)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1, 3, 6, 9, 12, 15, and 18 months

Awards & highlights

UPLIFT-AD Trial Summary

This trial will test whether the UPLIFT-AD model, which integrates primary and specialty palliative care, improves quality of life for nursing home residents with dementia and their caregivers, compared to usual care.

Who is the study for?

This trial is for long-stay residents in certain nursing homes who have moderate to severe Alzheimer's Disease, as confirmed by the Minimum Data Set (MDS), and have been there for over 30 days. Their family members or decision makers must speak English, as should the nursing facility staff involved.Check my eligibility

What is being tested?

The study tests UPLIFT-AD, a model integrating primary and specialty Palliative Care into nursing facilities for older adults with dementia. It includes educating staff on Palliative Care, training them to provide it, and offering specialty care consultations.See study design

What are the potential side effects?

Since this trial focuses on non-medical interventions like education and training in palliative care approaches rather than drugs or medical procedures, traditional side effects are not applicable. However, changes in resident health and quality of life will be monitored.

UPLIFT-AD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a long-term resident not using Medicare Part A for payment.

Select...

I have been diagnosed with moderate to severe Alzheimer's or dementia.

UPLIFT-AD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1, 3, 6, 9, 12, 15, and 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1, 3, 6, 9, 12, 15, and 18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1, 3, 6, 9, 12, 15, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in End-of-Life Dementia - Comfort Assessment In Dying scale (EOLD-CAD)

Secondary outcome measures

Change in End of Life Dementia - Satisfaction with Care (EOLD-SWC) scale

Change in End of Life Dementia - Symptom Management Scale.

Change in Family Distress in Advanced Dementia Scale.

+6 more

UPLIFT-AD Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Nursing Home-level UPLIFT-AD interventionExperimental Treatment1 Intervention

The UPLIFT-AD intervention consists of three major components delivered at the level of the nursing home: 1) in-house PC champions trained to a) facilitate advance care planning conversations with residents with Alzheimer's Disease and Related Dementias and their surrogate decision-makers, b) screen and follow up on residents' Palliative Care needs and c) serve as a liaison to Palliative Care consultants; 2) specialty Palliative Care consultant support providing individual consults for residents with complex Palliative Care needs; and 3) education on primary Palliative Care offered to all clinical NH staff.

Group II: Usual CareActive Control1 Intervention

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor

980 Previous Clinical Trials

979,762 Total Patients Enrolled

University of Maryland, BaltimoreOTHER

688 Previous Clinical Trials

372,656 Total Patients Enrolled

National Institute on Aging (NIA)NIH

1,675 Previous Clinical Trials

28,018,885 Total Patients Enrolled

Media Library

Alzheimer's Disease Clinical Trial 2023: UPLIFT-AD Highlights & Side Effects. Trial Name: NCT04520698 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are actively engaged in this research endeavor?

"Affirmative. The clinical trial is recruiting, according to details posted on the clinicaltrials.gov website; it was initially listed on September 8th 2021 and most recently updated March 8th 2022. This study requires 2000 participants at one facility."

Answered by AI

Is this research still recruiting participants?

"Per clinicaltrials.gov, this medical research has opened its recruitment process for potential candidates on September 8th 2021 and updated the information most recently on March 8th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease

Kathleen T. Unroe 2021. "Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04520698.

All > Alzheimer Disease > Alzheimers Disease